The Board approved Audited financial results for the quarter/year ended 31/03/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Brawn Biotech Ltd's board, at its meeting on 26th May 2025, approved the audited financial results for Q4 FY25 and the full year ended 31st March 2025. The company reported a loss for the full year, with negative basic and diluted earnings per share. Operating cash flow swung sharply from a positive Rs. 143.23 lakhs in FY24 to a negative Rs. 164.28 lakhs in FY25, driven by large working-capital movements. While total assets grew from Rs. 1,458.88 lakhs to Rs. 2,048.80 lakhs, shareholder equity actually shrank from Rs. 506.50 lakhs to Rs. 336.23 lakhs as reserves were heavily eroded, and trade payables (current plus non-current) ballooned to roughly Rs. 1,595 lakhs. The statutory auditor, Rajiv Udai & Associates (Firm Reg. No. 18764N), issued a clean, unqualified opinion with no qualifications, going-concern flag, or emphasis of matter.
A second straight year of losses combined with negative operating cash flow and a sharp drop in equity reserves are red flags for the business. The clean audit opinion is reassuring, but shareholders should monitor liquidity closely given the steep rise in trade payables relative to the shrinking equity base.